Losartan Potassium Tablet, Film Coated
Product Images NDC 60760-876

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 60760-876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Losartan Structure)

Chemical structure of losartan potassium, showing the molecular arrangement of atoms including potassium ion (K+), chlorine, nitrogen, carbon, hydrogen, and oxygen atoms as part of the compound's molecular framework.*

FDA Label Image

Fig-1 (Losartan Fig 1)

A line graph comparing the percentage of patients with a primary endpoint over 66 months between Losartan Potassium and Atenolol. The graph shows time in months on the x-axis and percentage on the y-axis, with Losartan Potassium represented by a solid line and Atenolol by a dotted line. Adjusted risk reduction is noted as 13%.*

FDA Label Image

Fig-2 (Losartan Fig 2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Atenolol (dotted line) and Losartan Potassium (solid line). The graph includes an annotation of Adjusted Risk Reduction of 25% with a p-value of 0.001.*

FDA Label Image

Fig-3 (Losartan Fig 3)

A comparative forest plot chart showing hazard ratios with 95% confidence intervals for the primary composite endpoint and stroke (fatal/non-fatal) events between Losartan Potassium and Atenolol. The chart breaks down data by patient demographics including age, gender, race, ISH, diabetes status, and history of cardiovascular disease, illustrating event rates and favorability towards each drug.*

FDA Label Image

Fig-4 (Losartan Fig 4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, and the dotted line represents placebo, showing a risk reduction of 16.1% with Losartan Potassium (p=0.022). The x-axis is labeled 'Months' and the y-axis is '% patients with event.'*

FDA Label Image

876 (Losartan Potassium 50mg 30ct 60760 876 30)

Label for Losartan Potassium film-coated tablets, USP 50 mg, quantity of 30 tablets. Manufactured by MSN Laboratories Private Limited, Telangana, India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. Includes storage instructions to keep tablets at controlled room temperature and protect from light. Contains usual dosage advisory to see package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.